WHO declares monkeypox a global health emergency in split vote
Nine members of the WHO’s expert committee voted against the designation, while six voted in favour
The World Health Organisation has declared the monkeypox outbreak a global health emergency, the highest level of alert issued by the agency.
The WHO confirmed that the monkeypox outbreak represents a ‘public health emergency of international concern (PHEIC)’ on Saturday. This label is designed to instigate a coordinated international response and may unlock funding to collaborate on sharing vaccines and treatments.
Members of an expert committee met on Thursday last week to discuss the designation, after deciding against the emergency label in June. The vote was split, with nine members voting against and six voting in favour. WHO head Tedros Adhanom Ghebreyesus said he acted as a tiebreaker to resolve the vote.
Speaking to reporters on Saturday, he said: ‘Although I am declaring a public health emergency of international concern, for the moment this is an outbreak that is concentrated among men who have sex with men, especially those with multiple sexual partners.’
Tedros added that the risk of monkeypox is moderate globally, except in Europe which is considered high-risk. Before this decision, the ‘global emergency’ label only applied to the coronavirus pandemic and efforts to eradicate polio.
Monkeypox is a typically mild viral infection that is endemic in parts of west and central Africa. It spreads through close contact and can be identified by flu-like symptoms, distinctive rashes and lesions on the skin. So far this year, there have been more than 16,000 cases of the disease in more than 75 countries, and five deaths in Africa.
There has been a sharp increase in cases over the summer months in Europe.
For a full rundown on the vaccines and therapeutics available to combat the disease, read our recent article: Vaccine industry must help fight monkeypox and secure supply chains.
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance